EA202190544A1 - Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний - Google Patents
Применение распадающихся в полости рта таблеток рилузола для лечения заболеванийInfo
- Publication number
- EA202190544A1 EA202190544A1 EA202190544A EA202190544A EA202190544A1 EA 202190544 A1 EA202190544 A1 EA 202190544A1 EA 202190544 A EA202190544 A EA 202190544A EA 202190544 A EA202190544 A EA 202190544A EA 202190544 A1 EA202190544 A1 EA 202190544A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- oral cavity
- riluzol
- disposing
- tablets
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862764864P | 2018-08-16 | 2018-08-16 | |
| PCT/US2019/046709 WO2020037152A1 (en) | 2018-08-16 | 2019-08-15 | Use of riluzole oral disintigrating tablets for treating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190544A1 true EA202190544A1 (ru) | 2021-06-18 |
Family
ID=69525906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190544A EA202190544A1 (ru) | 2018-08-16 | 2019-08-15 | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний |
Country Status (14)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL299301A (en) * | 2020-06-24 | 2023-02-01 | Biohaven Therapeutics Ltd | Compositions and methods for the treatment of obsessive compulsive disorder |
| EP4240308A4 (en) * | 2020-10-05 | 2024-10-30 | Icahn School of Medicine at Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| LT4243797T (lt) | 2020-11-16 | 2026-06-10 | Orcosa Inc. | Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| CN114177153B (zh) * | 2021-12-20 | 2023-04-07 | 平顶山市第二人民医院 | 一种利鲁唑口崩片及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| WO2004047793A1 (en) * | 2002-11-26 | 2004-06-10 | Alk-Abelló A/S | Pharmaceutical allergen product |
| US9241902B2 (en) * | 2003-12-17 | 2016-01-26 | R.P. Scherer Technologies, Llc | Chewable soft capsules containing ungelatinized starch |
| ES2819303T3 (es) * | 2005-04-05 | 2021-04-15 | Univ Yale | Agentes moduladores del glutamato en el tratamiento de trastornos mentales |
| US20080260823A1 (en) * | 2007-04-20 | 2008-10-23 | Sciele Pharma, Inc. | Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea |
| WO2011019375A1 (en) * | 2009-08-10 | 2011-02-17 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| US9041556B2 (en) | 2011-10-20 | 2015-05-26 | Apple Inc. | Method for locating a vehicle |
| US9434704B2 (en) * | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| RS59490B1 (sr) * | 2014-11-21 | 2019-12-31 | Biohaven Therapeutics Ltd | Sublingvalna formulacija riluzola |
| CA2967659A1 (en) * | 2014-11-21 | 2016-05-26 | Biohaven Pharmaceutical Holding Company Ltd. | Sublingual administration of riluzole |
| US10258611B2 (en) * | 2014-11-26 | 2019-04-16 | Medicinova, Inc. | Combination of ibudilast and riluzole and methods of using same |
| DK3265448T3 (da) * | 2015-03-03 | 2022-03-28 | Biohaven Therapeutics Ltd | Riluzol-prodrugs og anvendelse deraf |
| MX2019009038A (es) * | 2017-01-31 | 2019-12-09 | L Manfredi Paolo | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
-
2019
- 2019-08-15 CN CN201980054201.0A patent/CN112584831A/zh active Pending
- 2019-08-15 SG SG11202100880VA patent/SG11202100880VA/en unknown
- 2019-08-15 ES ES19849456T patent/ES2987802T3/es active Active
- 2019-08-15 JP JP2021507740A patent/JP2021534160A/ja active Pending
- 2019-08-15 AU AU2019322889A patent/AU2019322889A1/en not_active Abandoned
- 2019-08-15 KR KR1020217007246A patent/KR20210045423A/ko not_active Ceased
- 2019-08-15 BR BR112021002692-4A patent/BR112021002692A2/pt not_active Application Discontinuation
- 2019-08-15 US US17/268,072 patent/US20210315865A1/en active Pending
- 2019-08-15 WO PCT/US2019/046709 patent/WO2020037152A1/en not_active Ceased
- 2019-08-15 MX MX2021001563A patent/MX2021001563A/es unknown
- 2019-08-15 EP EP19849456.9A patent/EP3836922B1/en active Active
- 2019-08-15 EA EA202190544A patent/EA202190544A1/ru unknown
-
2021
- 2021-01-28 PH PH12021550218A patent/PH12021550218A1/en unknown
- 2021-02-04 IL IL280657A patent/IL280657A/en unknown
- 2021-02-08 MX MX2024007642A patent/MX2024007642A/es unknown
-
2023
- 2023-10-19 JP JP2023179961A patent/JP2024010017A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024007642A (es) | 2024-07-04 |
| EP3836922A4 (en) | 2022-05-04 |
| JP2024010017A (ja) | 2024-01-23 |
| SG11202100880VA (en) | 2021-02-25 |
| WO2020037152A1 (en) | 2020-02-20 |
| AU2019322889A1 (en) | 2021-03-04 |
| PH12021550218A1 (en) | 2021-12-06 |
| EP3836922B1 (en) | 2024-08-07 |
| IL280657A (en) | 2021-03-25 |
| US20210315865A1 (en) | 2021-10-14 |
| EP3836922A1 (en) | 2021-06-23 |
| MX2021001563A (es) | 2021-06-15 |
| EP3836922C0 (en) | 2024-08-07 |
| CA3109769A1 (en) | 2020-02-20 |
| JP2021534160A (ja) | 2021-12-09 |
| ES2987802T3 (es) | 2024-11-18 |
| BR112021002692A2 (pt) | 2021-05-11 |
| CN112584831A (zh) | 2021-03-30 |
| KR20210045423A (ko) | 2021-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| PH12019500025A1 (en) | Cancer treatment combinations | |
| EA200870469A1 (ru) | Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| EA202190308A1 (ru) | Применение пролекарств рилузола для лечения болезни альцгеймера | |
| MX2021014774A (es) | Formulaciones de liberacion modificada y usos de las mismas. | |
| MX2021015447A (es) | Métodos de tratamiento del cáncer dirigidos a tumores fríos. | |
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| PH12019502651A1 (en) | Use of vibegron to treat overactive bladder | |
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| MX2026002937A (es) | Nuevas fenilalquilaminas y su uso en el tratamiento de trastornos psiquiatricos | |
| MX2026001173A (es) | Moduladores del potencial de receptor transitorio melastatina 3 (trpm3) para el tratamiento del dolor | |
| MX2026000979A (es) | Una forma farmaceutica solida de dosificacion bucodispersable de safinamida | |
| MX2021014093A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| JP2021521227A5 (cg-RX-API-DMAC7.html) | ||
| EA202092944A1 (ru) | Применение пероральных распадающихся таблеток рилузола для лечения заболеваний | |
| JP2025522146A5 (cg-RX-API-DMAC7.html) | ||
| AU2017299850A8 (en) | Solid forms of TTK inhibitor | |
| JP2023518430A5 (cg-RX-API-DMAC7.html) | ||
| MX2024001832A (es) | Nueva composicion farmaceutica oral para terapias contra el cancer. | |
| JP2017509683A5 (cg-RX-API-DMAC7.html) | ||
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. |